{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:21:26Z","timestamp":1773433286070,"version":"3.50.1"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.intimp.2024.112419","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T12:38:30Z","timestamp":1718109510000},"page":"112419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Immune checkpoint inhibitors and SARS-CoV2 infection"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-5803","authenticated-orcid":false,"given":"Samaneh","family":"Abdolmohammadi-Vahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behzad","family":"Baradaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian M.","family":"Adcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7753-9624","authenticated-orcid":false,"given":"Esmaeil","family":"Mortaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.intimp.2024.112419_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2024.112419_b0010","doi-asserted-by":"crossref","first-page":"e00299","DOI":"10.1128\/CMR.00299-20","article-title":"Critical determinants of cytokine storm and type I interferon response in COVID-19 pathogenesis","volume":"34","author":"Ramasamy","year":"2021","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.intimp.2024.112419_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.563085","article-title":"COVID-19: molecular and cellular response","volume":"11","author":"Alipoor","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112419_b0020","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000514202","article-title":"Dynamic changes of lymphocyte subsets in the course of covid-19","volume":"182","author":"Rezaei","year":"2021","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.intimp.2024.112419_b0025","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112419_b0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112419_b0045","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112419_b0050","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112419_b0055","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1128\/JVI.02851-13","article-title":"Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells","volume":"88","author":"Rutigliano","year":"2014","journal-title":"J. Virol."},{"issue":"7077","key":"10.1016\/j.intimp.2024.112419_b0060","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.intimp.2024.112419_b0065","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.4049\/jimmunol.0800997","article-title":"Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion","volume":"182","author":"Bucks","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.112419_b0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omtm.2020.11.002","article-title":"Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection","volume":"20","author":"Sharif-Askari","year":"2021","journal-title":"Mol. Ther.-Meth. Clin. Develop."},{"issue":"5","key":"10.1016\/j.intimp.2024.112419_b0075","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112419_b0080","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112419_b0085","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/cancers12020371","article-title":"Immunotherapy by immune checkpoint inhibitors and nuclear medicine imaging: current and future applications","volume":"12","author":"Decazes","year":"2020","journal-title":"Cancers"},{"issue":"7109","key":"10.1016\/j.intimp.2024.112419_b0090","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.112419_b0095","series-title":"Safety, Immunologic and Virologic Activity of Anti-PD-L1 in HIV-1 Participants on ART","author":"Eron","year":"2016"},{"issue":"2","key":"10.1016\/j.intimp.2024.112419_b0100","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3892\/mmr.2016.5396","article-title":"CD28 family of receptors on T cells in chronic HBV infection: expression characteristics, clinical significance and correlations with PD-1 blockade","volume":"14","author":"Tang","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"23","key":"10.1016\/j.intimp.2024.112419_b0105","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.4254\/wjh.v7.i23.2449","article-title":"Programmed death-1\/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy","volume":"7","author":"Salem","year":"2015","journal-title":"World J. Hepatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112419_b0110","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.pulmoe.2021.03.008","article-title":"The immune response to SARS-CoV-2 and COVID-19 immunopathology\u2013current perspectives","volume":"27","author":"Boechat","year":"2021","journal-title":"Pulmonology"},{"issue":"6","key":"10.1016\/j.intimp.2024.112419_b0115","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.cell.2020.08.001","article-title":"Severe COVID-19 is marked by a dysregulated myeloid cell compartment","volume":"182","author":"Schulte-Schrepping","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.112419_b0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.thromres.2020.05.006","article-title":"The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: a retrospective study in Suzhou China","volume":"192","author":"Fu","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.intimp.2024.112419_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118102","article-title":"Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions","volume":"257","author":"Jafarzadeh","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0130","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1038\/s41467-020-17240-2","article-title":"Immunological and inflammatory profiles in mild and severe cases of COVID-19","volume":"11","author":"Song","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.112419_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.861251","article-title":"Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates","volume":"13","author":"Malengier-Devlies","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0140","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12985-022-01926-8","article-title":"Characteristics of lymphocyte subset alterations in COVID-19 patients with different levels of disease severity","volume":"19","author":"Dai","year":"2022","journal-title":"Virol. J."},{"key":"10.1016\/j.intimp.2024.112419_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.624483","article-title":"T-helper cell subset response is a determining factor in COVID-19 progression","volume":"11","author":"Gil-Etayo","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/JLB.4COVCRA0820-481RRR","article-title":"Neutrophils mediate Th17 promotion in COVID-19 patients","volume":"109","author":"Parackova","year":"2021","journal-title":"J. Leucoc. Biol."},{"key":"10.1016\/j.intimp.2024.112419_b0155","doi-asserted-by":"crossref","first-page":"1077236","DOI":"10.3389\/fimmu.2023.1077236","article-title":"Immune responses in mildly versus critically ill COVID-19 patients","volume":"14","author":"Nasrollahi","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112419_b0160","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4049\/jimmunol.2000554","article-title":"A case for targeting Th17 cells and IL-17A in SARS-CoV-2 infections","volume":"205","author":"Orlov","year":"2020","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112419_b0165","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1136\/gutjnl-2020-321269","article-title":"COVID-19 and immunomodulation in IBD","volume":"69","author":"Neurath","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2024.112419_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101495","article-title":"T helper type (Th1\/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: from cytokines produced to immune responses","volume":"70","author":"Aleebrahim-Dehkordi","year":"2022","journal-title":"Transpl. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112419_b0175","article-title":"SARS-CoV-2-specific T cells exhibit phenotypic features of helper function, lack of terminal differentiation, and high proliferation potential","volume":"1","author":"Neidleman","year":"2020","journal-title":"Cell Rep. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.112419_b0180","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Moderbacher","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0185","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2024.112419_b0190","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.immuni.2020.07.026","article-title":"Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses","volume":"53","author":"Zhou","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0195","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1038\/s41467-020-17292-4","article-title":"Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia","volume":"11","author":"De Biasi","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.intimp.2024.112419_b0200","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade TherapyFundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.intimp.2024.112419_b0205","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti\u2013CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2020.09.009","article-title":"Compartmental immunophenotyping in COVID-19 ARDS: a case series","volume":"147","author":"Ronit","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112419_b0215","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1 (PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr. Opin. Immunol."},{"issue":"1\u20133","key":"10.1016\/j.intimp.2024.112419_b0220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3\u03b6 signalosome and downstream signaling to PKC\u03b8","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett."},{"issue":"230","key":"10.1016\/j.intimp.2024.112419_b0225","doi-asserted-by":"crossref","first-page":"ra46-ra46","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0230","first-page":"1","article-title":"Programmed cell death protein 1 (PD-1) molecule in coronavirus disease 2019 (COVID-19)?","volume":"20","author":"Mortaz","year":"2021","journal-title":"Tanaffos"},{"issue":"9","key":"10.1016\/j.intimp.2024.112419_b0235","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/infdis\/jiab061","article-title":"Increased PD-L1 expression may be associated with the cytokine storm and CD8+ T-cell exhaustion in severe COVID-19","volume":"223","author":"Chen","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.intimp.2024.112419_b0240","first-page":"1","article-title":"The effect of COVID-19 derived cytokine storm on cancer cells progression: double-edged sword","author":"Heydarian","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.intimp.2024.112419_b0245","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.2147\/OTT.S170385","article-title":"TIM-3, a promising target for cancer immunotherapy","volume":"11","author":"He","year":"2018","journal-title":"Onco Targets Ther."},{"issue":"9","key":"10.1016\/j.intimp.2024.112419_b0250","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid\u2013mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0255","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2024.112419_b0260","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/82_2010_114","article-title":"LAG-3 in cancer immunotherapy","volume":"344","author":"Goldberg","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.intimp.2024.112419_b0265","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/eji.1830250949","article-title":"CD4\/major histocompatibility complex class II interaction analyzed with CD4-and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins","volume":"25","author":"Huard","year":"1995","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112419_b0270","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2024.112419_b0275","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3389\/fimmu.2020.01870","article-title":"Schulze zur Wiesch, Analysis of co-inhibitory receptor expression in COVID-19 infection compared to acute plasmodium falciparum malaria: lAG-3 and TIM-3 correlate with t cell activation and course of disease","volume":"11","author":"Herrmann","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112419_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.870283","article-title":"Inhibitory immune checkpoint receptors and ligands as prognostic biomarkers in COVID-19 patients","volume":"13","author":"Al-Mterin","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0285","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a key inhibitor of the cancer immunity cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112419_b0290","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112419_b0295","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.4049\/jimmunol.2100446","article-title":"The quality of SARS-CoV-2\u2013specific T cell functions differs in patients with mild\/moderate versus severe disease, and T cells expressing coinhibitory receptors are highly activated","volume":"207","author":"Shahbaz","year":"2021","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112419_b0300","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.celrep.2019.07.073","article-title":"Structure and functional binding epitope of V-domain Ig suppressor of T cell activation","volume":"28","author":"Mehta","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2024.112419_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.625808","article-title":"Structural basis of VSIG3: the ligand for VISTA","volume":"12","author":"Xie","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112419_b0310","doi-asserted-by":"crossref","first-page":"e202000955","DOI":"10.26508\/lsa.202000955","article-title":"Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression","volume":"4","author":"Rendeiro","year":"2021","journal-title":"Life Sci. Alliance"},{"issue":"2","key":"10.1016\/j.intimp.2024.112419_b0315","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.immuni.2020.06.024","article-title":"Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease","volume":"53","author":"Schulthei\u00df","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2024.112419_b0320","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.654960","article-title":"Roles of BTLA in immunity and immune disorders","volume":"12","author":"Ning","year":"2021","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112419_b0325","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.573","article-title":"The immune checkpoints storm in COVID-19: role as severity markers at emergency department admission","volume":"11","author":"Avenda\u00f1o-Ortiz","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"11","key":"10.1016\/j.intimp.2024.112419_b0330","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"590","key":"10.1016\/j.intimp.2024.112419_b0335","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf7517","article-title":"T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals","volume":"13","author":"Bilich","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.intimp.2024.112419_b0340","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/s41423-021-00750-4","article-title":"Activation or exhaustion of CD8+ T cells in patients with COVID-19","volume":"18","author":"Rha","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"39","key":"10.1016\/j.intimp.2024.112419_b0345","doi-asserted-by":"crossref","first-page":"24384","DOI":"10.1073\/pnas.2015486117","article-title":"Suboptimal SARS-CoV-2\u2212 specific CD8+ T cell response associated with the prominent HLA-A* 02: 01 phenotype","volume":"117","author":"Habel","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2024.112419_b0350","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"issue":"34","key":"10.1016\/j.intimp.2024.112419_b0355","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg4081","article-title":"Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection","volume":"7","author":"Yatim","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0360","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.immuni.2020.12.002","article-title":"PD-1-expressing SARS-CoV-2-specific CD8+ T cells are not exhausted, but functional in patients with COVID-19","volume":"54","author":"Rha","year":"2021","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.intimp.2024.112419_b0365","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.3390\/cancers12113383","article-title":"Cancer and immune checkpoint inhibitor treatment in the era of SARS-CoV-2 infection","volume":"12","author":"Gambichler","year":"2020","journal-title":"Cancers"},{"issue":"7340","key":"10.1016\/j.intimp.2024.112419_b0370","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/471561a","article-title":"Melanoma drug wins US approval","volume":"471","author":"Ledford","year":"2011","journal-title":"Nature"},{"issue":"6230","key":"10.1016\/j.intimp.2024.112419_b0375","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.intimp.2024.112419_b0380","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","article-title":"Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical TrialPreoperative CTLA-4 blockade","volume":"16","author":"Carthon","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2024.112419_b0385","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/2326-6066.CIR-13-0020","article-title":"Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 TherapyICOS+ T cells as a pharmacodynamic marker","volume":"1","author":"Ng Tang","year":"2013","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.intimp.2024.112419_b0390","article-title":"Adjunct immunotherapies for the management of severely ill COVID-19 patients","volume":"1","author":"Bonam","year":"2020","journal-title":"Cell Rep. Med."},{"issue":"26","key":"10.1016\/j.intimp.2024.112419_b0395","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7528","key":"10.1016\/j.intimp.2024.112419_b0400","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.intimp.2024.112419_b0405","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.112419_b0410","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune EscapeLAG-3 and PD-1 synergistically prevent antitumor immunity","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2024.112419_b0415","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"20","key":"10.1016\/j.intimp.2024.112419_b0420","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","article-title":"PD-1 blockade enhances T-cell migration to tumors by elevating IFN-\u03b3 inducible ChemokinesPD-1 blockade improves the effectiveness of ACT for cancer","volume":"72","author":"Peng","year":"2012","journal-title":"Cancer Res."},{"issue":"7528","key":"10.1016\/j.intimp.2024.112419_b0425","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.intimp.2024.112419_b0430","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1084\/jem.20061496","article-title":"PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection","volume":"203","author":"Petrovas","year":"2006","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.112419_b0435","doi-asserted-by":"crossref","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection","volume":"8","author":"Gardiner","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.intimp.2024.112419_b0440","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.112419_b0445","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/ijms18030645","article-title":"TIM-3 as a target for cancer immunotherapy and mechanisms of action","volume":"18","author":"Du","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2024.112419_b0450","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/eji.201141852","article-title":"Blockade of T im-3 signaling restores the virus-specific CD 8+ T-cell response in patients with chronic hepatitis B","volume":"42","author":"Wu","year":"2012","journal-title":"Eur. J. Immunol."},{"issue":"15","key":"10.1016\/j.intimp.2024.112419_b0455","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2019.37.15_suppl.2508","article-title":"First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), \u00b1cemiplimab in patients (pts) with advanced malignancies","volume":"37","author":"Papadopoulos","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.intimp.2024.112419_b0460","article-title":"Phase I\/II study of LAG525\u00b1spartalizumab (PDR001) in patients (pts) with advanced malignancies","volume":"36","author":"Hong","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.intimp.2024.112419_b0465","article-title":"A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms","volume":"38","author":"Luke","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.intimp.2024.112419_b0470","article-title":"Pushing the accelerator and releasing the brake: a phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma","volume":"36","author":"Eastgate","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005349","article-title":"TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection","volume":"12","author":"Chew","year":"2016","journal-title":"PLoS Pathog."},{"issue":"5","key":"10.1016\/j.intimp.2024.112419_b0480","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0485","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41392-020-00308-2","article-title":"Storm of soluble immune checkpoints associated with disease severity of COVID-19","volume":"5","author":"Kong","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"16_Supplement","key":"10.1016\/j.intimp.2024.112419_b0490","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-CT406","article-title":"Abstract CT406: patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak","volume":"80","author":"Dai","year":"2020","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2024.112419_b0495","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/2326-6066.CIR-21-0008","article-title":"At the crossroads: COVID-19 and immune-checkpoint blockade for cancer","volume":"9","author":"Garassino","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.intimp.2024.112419_b0500","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0505","doi-asserted-by":"crossref","first-page":"e001931","DOI":"10.1136\/jitc-2020-001931","article-title":"Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition","volume":"9","author":"Rogiers","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0510","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1038\/s41467-020-17834-w","article-title":"Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm","volume":"11","author":"Guo","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.112419_b0515","unstructured":"Immunoregulatory Therapy for 2019-nCoV, https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04268537."},{"key":"10.1016\/j.intimp.2024.112419_b0520","unstructured":"Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection (NIVISCO), https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04413838."},{"key":"10.1016\/j.intimp.2024.112419_b0525","unstructured":"Trial Evaluating Efficacy and Safety of Nivolumab (Optivo\u00ae) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort. (CORIMUNO-NIVO), https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04343144."},{"key":"10.1016\/j.intimp.2024.112419_b0530","unstructured":"COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1, https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04356508."},{"key":"10.1016\/j.intimp.2024.112419_b0535","unstructured":"Checkpoint Blockade in COVID-19 Pandemic (COPERNICO), https:\/\/clinicaltrials.gov\/study\/NCT04335305?tab=history."},{"key":"10.1016\/j.intimp.2024.112419_b0540","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijid.2022.08.007","article-title":"Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): a randomized proof-of-concept phase II study","volume":"123","author":"S\u00e1nchez-Conde","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.intimp.2024.112419_b0545","unstructured":"Immune Modulators for Treating COVID-19 (ACTIV-1 IM). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04593940."},{"issue":"4","key":"10.1016\/j.intimp.2024.112419_b0550","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jama.2023.11043","article-title":"Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized With COVID-19 pneumonia: a randomized clinical trial","volume":"330","author":"O\u2019Halloran","year":"2023","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.intimp.2024.112419_b0555","unstructured":"Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise, https:\/\/clinicaltrials.gov\/study\/NCT04472494?tab=history&a=5."},{"key":"10.1016\/j.intimp.2024.112419_b0560","unstructured":"Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial, https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05822583."},{"key":"10.1016\/j.intimp.2024.112419_b0565","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijid.2023.11.021","article-title":"Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: results of a propensity-matched analysis of the OnCovid registry","volume":"139","author":"Mostaghim","year":"2024","journal-title":"Int. J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2024.112419_b0570","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41423-020-0450-7","article-title":"NKG2A and COVID-19: another brick in the wall","volume":"17","author":"Antonioli","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112419_b0575","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/17534259221077750","article-title":"Natural killer cell exhaustion in SARS-CoV-2 infection","volume":"28","author":"Gallardo-Zapata","year":"2022","journal-title":"Innate Immun."},{"key":"10.1016\/j.intimp.2024.112419_b0580","unstructured":"Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection (IMMUNONCOVID), https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04333914."},{"issue":"9","key":"10.1016\/j.intimp.2024.112419_b0585","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1096\/fj.15-271635","article-title":"Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin","volume":"29","author":"Russkamp","year":"2015","journal-title":"FASEB J."},{"issue":"12","key":"10.1016\/j.intimp.2024.112419_b0590","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1097\/CCM.0000000000005683","article-title":"Avdoralimab (Anti-C5aR1 mAb) versus placebo in patients with severe COVID-19: results from a randomized controlled trial (FOR COVID Elimination [FORCE])","volume":"50","author":"Carvelli","year":"2022","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.intimp.2024.112419_b0595","unstructured":"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia (FORCE) (FORCE), https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04371367."},{"issue":"7","key":"10.1016\/j.intimp.2024.112419_b0600","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1172\/JCI40040","article-title":"PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice","volume":"120","author":"Mueller","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"13","key":"10.1016\/j.intimp.2024.112419_b0605","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1084\/jem.20121015","article-title":"Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice","volume":"209","author":"Frebel","year":"2012","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.intimp.2024.112419_b0610","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3390\/vaccines11101563","article-title":"Usp22 deficiency leads to downregulation of PD-L1 and pathological activation of CD8+ T cells and causes immunopathology in response to acute LCMV infection","volume":"11","author":"Friebus-Kardash","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.intimp.2024.112419_b0615","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fphar.2020.00557","article-title":"Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database","volume":"11","author":"Ceschi","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112419_b0620","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.lungcan.2020.05.006","article-title":"Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?","volume":"145","author":"Di Noia","year":"2020","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"11","key":"10.1016\/j.intimp.2024.112419_b0625","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1159\/000509941","article-title":"Immune checkpoint inhibitor-related pneumonitis","volume":"99","author":"Gomatou","year":"2021","journal-title":"Respiration"},{"key":"10.1016\/j.intimp.2024.112419_b0630","series-title":"Seminars in Oncology","first-page":"362","article-title":"A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients","author":"Cortellini","year":"2019"},{"issue":"10229","key":"10.1016\/j.intimp.2024.112419_b0635","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.intimp.2024.112419_b0640","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/14712598.2021.1887131","article-title":"Immune checkpoint inhibition in COVID-19: risks and benefits","volume":"21","author":"Pezeshki","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2024.112419_b0645","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-0304-7","article-title":"Fighting COVID-19 exhausts T cells","volume":"20","author":"Moon","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112419_b0650","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/imt-2020-0067","article-title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors","volume":"12","author":"Bersanelli","year":"2020","journal-title":"Immunotherapy"},{"issue":"12","key":"10.1016\/j.intimp.2024.112419_b0655","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non\u2013small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112419_b0660","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor\u2013related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0665","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1186\/s12885-023-11584-w","article-title":"Association of immune-related adverse events with COVID-19 pneumonia in lung cancer patients receiving immune checkpoint inhibitors: a cross-sectional study in China","volume":"23","author":"Che","year":"2023","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2024.112419_b0670","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.intimp.2024.112419_b0675","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2024.112419_b0680","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA111","article-title":"Thoracic cancers international COVID-19 collaboration (TERAVOLT): impact of type of cancer therapy and COVID therapy on survival","volume":"38","author":"Horn","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112419_b0685","doi-asserted-by":"crossref","first-page":"103","DOI":"10.36401\/JIPO-22-24","article-title":"COVID-19 outcomes in patients with cancer receiving immune checkpoint inhibitors: a systematic review","volume":"6","author":"Ruiz","year":"2023","journal-title":"J. Immunother. Precis. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112419_b0690","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2207438","article-title":"Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors","volume":"19","author":"Gilbert","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"issue":"8","key":"10.1016\/j.intimp.2024.112419_b0695","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jtho.2022.05.015","article-title":"Safety and immunogenicity of mRNA vaccines against severe acute respiratory syndrome coronavirus 2 in patients with lung cancer receiving immune checkpoint inhibitors: a multicenter observational study in Japan","volume":"17","author":"Hibino","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112419_b0700","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.6004\/jnccn.2022.7048","article-title":"Immune-related adverse events among COVID-19\u2013vaccinated patients with cancer receiving immune checkpoint blockade","volume":"20","author":"Widman","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"3","key":"10.1016\/j.intimp.2024.112419_b0705","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004157","article-title":"Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study","volume":"10","author":"Mei","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2024.112419_b0710","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11547-023-01598-6","article-title":"Immune checkpoint inhibitor-related pneumonitis and COVID-19: a case-matched comparison of CT findings","volume":"128","author":"Picasso","year":"2023","journal-title":"Radiol. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924009408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924009408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T15:35:03Z","timestamp":1720280103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924009408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":142,"alternative-id":["S1567576924009408"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112419","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors and SARS-CoV2 infection","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112419"}}